Author Archives: admin


Stem Cell Clinic > Articles by: admin

Whats Happening: IDF Shabbat of Heroes, Sephardic Papers – Jewish Journal

By Adult Stem Cells

FRI DEC 6

Zamru Friday NightShomrei Torah Synagogue holds Zamru Friday Night, a unique, musically rich kabbalat Shabbat service and dinner. Cantor Jackie Rafii and guitarist Daniel Raijman headline the event, Music to Move Your Soul. Guests bring their own kosher wine. 6-9 p.m. Dinner for members: $20 adults, $12 children 12 and under. General: $30 adults, $15 children. Shomrei Torah Synagogue, 7353 Valley Circle Blvd., West Hills. (818) 854-7650.

Middle East DiscussionGiven decades of conflict between the same rivals, punctuated by intermittent treaties, the Middle East is arguably the politically messiest region on earth. Jordan Reimer, policy analyst at the RAND Corp., helps to unpack the conflicts. A scholar who served under two White House administrations and the New York City Police Department, Reimer explains effects of the constant conflicts in the Middle East on Israel and the United States. 6:15 p.m. service. 7:30-9 p.m. lecture. Temple Isaiah, 10345 W. Pico Blvd. (310) 277-2772.

IKAR FeastIt is the first Friday of the month again, which means its time for IKARs monthly TRIBE Feast, a schmooze and groove at food-filled tables with Jewish and Jew-adjacent 20- and 30-somethings. RSVP requested so sufficient food is prepared. 6:30 p.m. Shabbat service. 7:45 p.m. TRIBE Feast. IKARs Event Space, 1729 S. La Cienega Blvd. (323) 634-1870.

Shabbat for WomenLev Eisha, a community of and for joyous Jewish women, celebrates a Shabbat infused with music and enlightened by teachings by Rabbi Toba August. She and cantorial soloist Cindy Paley lead Shabbat services. Everybody is welcome. 8:15 a.m. teaching. 9:30 a.m. service. Beth Shir Shalom, 1827 California Ave., Santa Monica. (310) 575-0985.

Max & Willys Last LaughWhen German comedian Max Ehrlich and his best friend, composer Willy Rosen, were caught in Holland in 1942 and sent to a concentration camp, the commandant recognized Ehrlich. He made an irresistible offer: Every Monday night before the train leaves for Auschwitz, Max and Willy will perform a cabaret. If they are funny, they will perform it the following week. If not, they will be put on the train. The performers carried on for 18 months before finally being sent to Auschwitz. Tonight and Sunday afternoon, Temple Emanuel of Beverly Hills presents a staged reading with live music of Max and Willys Last Laugh. Proceeds benefit Temple Emanuel of Beverly Hills. 8 p.m. tonight, 5 p.m. Sunday. $100 reserved seats, $36 general admission, $18 students. James Bridges Theater at UCLA, 235 Charles E. Young Drive East. (310) 825-6792.

Beth Am Film NightAfter Shabbat ends, Temple Beth Am resumes its film series with Laces, the story of a special needs sons complex relationship with the aging father who abandoned him when he was a child. Film buff Michael Berlin leads a post-film discussion. Snacks served. 7 p.m. $12. Temple Beth Am, 1039 S. La Cienega Blvd. (310) 652-7353.

Shulem Lemmer

Our IDF HeroesAfter a Shabbat of Heroes at Pico-Robertson synagogues Adas Torah, Beth Jacob, Bnai David-Judea and Young Israel of Century City, a meet and greet with heroes of the Israel Defense Forces (IDF) takes place at The Mark. Ezer Mizion, the worlds largest Jewish bone marrow registry, organizes this gathering, highlighting how as of August, 2,000 IDF soldiers have donated their stem cells to 2,000 patients around the world. The evening features musician Shulem Lemmer performing during Havdalah and former Israeli Chief Rabbi Yisrael Meir Lau bringing greetings from the Jewish state. Israeli wines and food served. Adults only. RSVP required. 7:30 p.m. The Mark, W. 9320 Pico Blvd. (310) 247-2266.

Sarah Abrevaya Stein

Family Papers: A Sephardic JourneyFor centuries from the Greek port city of Salonica, the large Levy family of editors and publishers reported how the ever-changing state of modernity affected Sephardic Jews across the Ottoman Empire, including how 20th-century wars altered the borders around them. Historian Sarah Abrevaya Stein shares the true story of a frayed family that has been preserved through their letters. She discusses her award-winning book, Family Papers: A Sephardic Journey Through the Twentieth Century, with race and gender scholar Brenda E. Stevenson. 2 p.m. Free. Skirball Cultural Center, 2701 N. Sepulveda Blvd. (310) 440-4500.

Community Service DayAttention all people who seek to make a difference immediately: The Jewish Federation of Greater Los Angeles Community Service Day lasts all day and is a partnership between Federation and social service organizations working to make life better for their neighbors. Free. Prior registration required. For more information, email volunteer@jewishla.org.

The Golden Gelt RoomJoin the Congregation Kol Ami community in The Golden Gelt Room, for an afternoon of comedy, casino games and pre-Hanukkah celebration. Comedian Liz Glazer performs. Mingle, nosh, drink, play and laugh with Kol Amis inclusive community. 4-6:30 p.m. $100. Congregation Kol Ami, 1200 N. La Brea Ave., West Hollywood. (323) 606-0996..

Hanukkah Angels Gift-Wrapping EventThere still is time to become a Hanukkah Angel in Kehillat Maaravs community mitzvah program. Purchase a gift of any amount for one of 10 Chai Lifeline children with life-threatening illnesses, then bring it to the synagogue starting at 9 a.m. and join the synagogues religious school students in gift-wrapping from 11:30 a.m.-12:30 p.m. Latkes and sufganiyot served. To learn about each childs wish list or to become a Hanukkah Angel, contact Rose or Sharone Weizman at eddirector@km-synagogue.org. 1715 21st St., Santa Monica. (310) 829-0566.

Jewish ID Hanukkah PartyEven though Hanukkah doesnt start for two weeks, Jewish Big Brothers Big Sisters of Los Angeles (JBBBSLA) starts early. Bring the children to Stephen Wise Temple for a huge Hanukkah celebration co-organized by JBBBSLA and Kibbutz Bob Waldorf. Ideal for all ages. Candlemaking, Israeli dancing, dreidel games and camp activities highlight the event. If the $5 per person charge is too expensive (children 3-and-under are admitted free), contact Sofia Varona at (323) 456-1162 or sofia@campbobwaldorf.org. 4 p.m. $5. Stephen Wise Temple, 15500 Stephen S. Wise Drive.

BYTHAX Gospel Choir

Hanukkah and Christmas ConcertWilshire Boulevard Temple stages a performance of peace, love and harmony. The congregations Let There Be Light concert of Hanukkah and Christmas melodies, co-organized by the Faithful Central Bible Church, features performers Dr. Dee, the BYTHAX Gospel Choir, Cantor Don Gurney and the Wilshire Boulevard Temple Adult Choir. Sufganiyot and holiday cookies are served after the concert. 4 p.m. Free. RSVP required. Wilshire Boulevard Temple, 3663 Wilshire Blvd. (213) 388-2401.

Lets Talk About ReligionIn the latest round of American Jewish Universitys (AJU) discussion series Lets Talk About Religion: Jews, Christians and Muslims in Conversation, a Jew and a Muslim examine rival and converging views on Is Life Sacred? Tonights topics are medical ethics, abortion and end-of-life issues, with Rabbi Elliot Dorff, rector and professor in philosophy at AJU, in discussion with Dr. Sana Khan, chairman and founder of theAiM Radiology Medical Group. 7:30-9 p.m. $10. American Jewish University, Alan Shapiro Memorial Synagogue, 15600 Mulholland Drive. (310) 440-1572.

The Holocaust and the Danish ExceptionThe Los Angeles Museum of the Holocaust holds a book signing and artists reception with acclaimed photographer Judy Glickman Lauder. Her photos are on exhibit in Beyond the Shadows: The Holocaust and the Danish Exception. Lauder, a Bay Area native, has been photographing Holocaust sites since the 1980s. She talks about her experiences. 7-8:30 p.m. $10 suggested donation. Los Angeles Museum of the Holocaust in Pan Pacific Park, 100 The Grove Drive. (323) 651-3704.

Have an event coming up? Send your information two weeks prior to the event to ryant@jewishjournal.com for consideration. For groups staging an event that requires an RSVP, please submit details about the event the week before the RSVP deadline.

Excerpt from:
Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal

Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Breaking News Updates

By Adult Stem Cells

The Global Stem Cells Market report study includes an elaborative summary of the Stem Cells market that provides in-depth knowledge of various different segmentations. Stem Cells Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Stem Cells Market. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps. Stem Cells delivers pin point analysis of varying competition dynamics and keeps ahead of Stem Cells competitors such as CCBC, Vcanbio, Boyalife, Beikebiotech.

View Sample Report @http://www.marketresearchstore.com/report/global-stem-cells-market-2019-by-manufacturers-regions-491303#RequestSample

The main objective of the Stem Cells report is to guide the user to understand the Stem Cells market in terms of its definition, classification, Stem Cells market potential, latest trends, and the challenges that the Stem Cells market is facing. In-depth researches and Stem Cells studies were done while preparing the Stem Cells report. The Stem Cells readers will find this report very beneficial in understanding the Stem Cells market in detailed. The aspects and information are represented in the Stem Cells report using figures, bar-graphs, pie diagrams, and other visual representations. This intensifies the Stem Cells pictorial representation and also helps in getting the Stem Cells industry facts much better.

.This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Geographically this report covers all the major manufacturers from India, China, the USA, the UK, and Japan. The present, past and forecast overview of the Stem Cells market is represented in this report.

The Study is segmented by following Product Type, Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Major applications/end-users industry are as follows Diseases Therapy, Healthcare

Stem Cells Market Report Highlights:

1)The report provides a detailed analysis of current and future market trends to identify the investment opportunities2) In-depth company profiles of key players and upcoming prominent players3) Global Stem Cells Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)4) Strategic recommendations in key business segments based on the market estimations5) To get the research methodologies those are being collected by Stem Cells driving individual organizations.

Research Parameter/ Research Methodology

Primary Research:

The primary sources involve the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In Secondary research crucial information about the industry value chain, the total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Inquiry for Buying Report: http://www.marketresearchstore.com/report/global-stem-cells-market-2019-by-manufacturers-regions-491303#InquiryForBuying

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

Continued here:
Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates

Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 – 2025 – Markets Gazette 24

By Adult Stem Cells

Detailed Study on the Marine Coatings Market

The latest report published by Transparency Market Research on the global Marine Coatings market reveals that the market is expected to grow at a CAGR of ~XX% during the forecast period (2019-2029) and reach a value of ~US$ XX by the end of 2019. Further, by leveraging the data in the report, investors, established players, emerging market players, and stakeholders can develop effective business strategies to cement their position in the global Marine Coatings market.

The report ponders over the micro and macro-economic factors that are expected to shape the growth of the Marine Coatings market in the upcoming decade. The report includes a SWOT analysis of some prominent players in the Marine Coatings market wherein the business prospects of each player are discussed in detail.

Concessions for new customers! Offer expires soon!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=902

Vital Market Information Included in the Report:

The report resolves the following doubts related to the Marine Coatings market:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=902

Marine Coatings Market Bifurcation

The Marine Coatings market is bifurcated into different sections to provide a clear understanding of the various aspects of the market. The growth potential, market share, size, and prospects of each segment and sub-segment is depicted in the report.

segmentation study, geographical analysis, vendor landscape study, and other aspects that could prove to be significant for ensuring a strong growth in the global stem cells market.

Global Stem Cells Market: Trends and Opportunities

The world stem cells market is predicted to attain favorable growth prospects on the back of the positive impact caused by swelling investments from biopharmaceutical and pharmaceutical companies for conducting stem cell research. Increasing incidence of chronic diseases could be another powerful factor augmenting the demand in the market. For the coming years, market growth is anticipated to be cemented with the rise of increasing research and development, high-quality stem cell banking facilities, and rising count of stem cell donors.

Amongst all major types, adult stem cells are projected to secure a high demand in the near future as they could multiply into scores of specialized cells capable of repairing tissue damage and lowering the risks of rejection. Budding segments such as induced pluripotent stem cells could also offer rewarding prospects in the market with the help of their unique traits and advantages.

Global Stem Cells Market: Geographical Analysis

The international stem cells market is foreseen to testify the dominance of North America which has always been at the forefront of the adoption of latest technologies. Besides its impressive technological progress, the region could improve its growth while riding on the increasing prevalence of target chronic disorders, high economic growth, and massive investments in the industry. As a result, the regional market is forecast to showcase a colossal growth in the coming years.

Treading on the heels of North America, Europe could also provide lucrative growth opportunities in the international stem cells market due to factors such as medical tourism. An increasing number of U.S. and Canada patients have been witnessed to travel to Europe for taking treatments made available at economical costs. Asia Pacific is envisioned to exhibit a relatively slower growth in the market due to various reasons.

Global Stem Cells Market: Companies Mentioned

With a view to expand their presence as well as their portfolios when operating in the worldwide stem cells market, players are foretold to work out strategic partnerships and collaborations with pharmaceutical firms. Moreover, they could look to raise funds with the help of overseas organizations to introduce new stem cell-based therapies in the market. Some of the leading companies in the market could be Cellular Engineering Technologies Inc., Astellas Pharma Inc., and STEMCELL Technologies Inc.

Global Stem Cells Market by Product

Global Stem Cells Market by Source

Global Stem Cells Market by Application

Global Stem Cells Market by End User

Global Stem Cells Market by Geography

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=902

What Sets TMR Apart From the Rest?

See the rest here:
Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24

‘I was given a terminal diagnosis and then a new therapy cured my leukaemia’ – The Telegraph

By Stem Cell Doctors

When my GP assessed me, he just couldnt explain it, she recalls. Referred to Heartlands Hospital, Sophie was given a blood test. By then I was sitting on a ward. Everyone else was 60-plus and had leukaemia and I thought Well, I havent got that. I was 20.

Finally she was called into a tiny consultation room. The doctor had his head in his hands. I literally dont believe it, he told Sophie. Its leukaemia.

In the blink of an eye, Sophies old life ended. She called her parents (You better hurry up because its not good) and was immediately admitted to hospital. Diagnosed on Friday, treatment began on Monday. So swiftly did it begin that there was no time to think about side-effects. No time for saving fertility or anything like that, she recalls matter-of-factly, her bright Chelmsley Wood accent belying the astonishing gravity of her experience.

Her hair started falling out. She had Acute lymphoblastic leukaemia (ALL), one of the four types of life-threatening, acute leukaemia. (Other non-curable but largely non-fatal forms of the disease are known as chronic leukaemia.)Of the 10,000 or so people diagnosed with leukaemia in the UK each year, about 350 have ALL.

There are no official statistics but estimates suggest that five-year ALL survival rates for 15-24 year-olds are about 70pc. One of the key factors affecting that survival, however, is early diagnosis. To put it bluntly, if any cancer has progressed so far that patients walk straight in to A&E, bypassing their GP, it bodes poorly.

Visit link:
'I was given a terminal diagnosis and then a new therapy cured my leukaemia' - The Telegraph

Stem Cell Therapy Market Robust pace of Industry during 2017-2025 – News Description

By Stem Cell Doctors

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the Market CLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @ CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Report for more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

The rest is here:
Stem Cell Therapy Market Robust pace of Industry during 2017-2025 - News Description

A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives – Economic Times

By Stem Cell Doctors

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

Continued here:
A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives - Economic Times

Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 – Wolf Mirror

By Induced Pluripotent Stem Cells

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Follow this link:
Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 - Wolf Mirror

Kyoto University Seeking To Use Stem Cells On Knee Treatment – Anti Aging News

By Induced Pluripotent Stem Cells

Kyoto University has asked the government of Japan for approval to conduct a human clinical trial involving transplanting cartilage made from induced pluripotent stem cells as an approach to treat damaged knee joints.

Led by Professor Noriyuki Tsumaki the research team will be culturing iPS cells to create cartilage tissue which will be used to transplant into knees; according to the University the team submitted the study plan to the health ministry on November 7, 2019 for review by its special panel.

Their treatment approach has already been tested in animal studies where it was found to be effective and shown to carry a low risk of rejection, cancerization, and fibrosis reaction, according to the Kyoto research team.

Their plan which includes its safety was approved in October by a University board, which is hoped to help treat patients with degenerated or damaged cartilage due to injuries or illness. Cartilage tissue covers joint bones and absorbs shock, joints are not able to move smoothly if the cartilage is damaged or if it turns fibrous with age.

The Kyoto team hopes that this treatment will be an improvement on current methods in which cartilage tissue is transplanted as it is hard to acquire tissues, and the transplanted tissues often tend to turn fibrous to help effectively treat damaged knee joints.

Follow this link:
Kyoto University Seeking To Use Stem Cells On Knee Treatment - Anti Aging News

Story of a 15-year old scientist: How it all began – EuroScientist

By Induced Pluripotent Stem Cells

Children and young adults these days have awide range of possibilities how to spend their leisure time. Some of us like to watch movies, some of us enjoy playing aflute and some of us prefer to go laboratories, put on a white coat and carry out an experiment. Zuzana Hudov, a15-year old student from Slovakia, fell into the category of teenagers who preferred going to labs and make experiments. Even though this is just onestory it once may be astory of hundreds of young aspiring students.

As alittle child Zuzanawas not much different from all the other kids in the kindergarten. Shewas playful, energetic and endlessly curious about the world surrounding her. However, curiosity diverted from the behaviour of her classmates. Most of the kids liked to explore the outside world, yet Zuzanawas more fascinated about the things that could not be understood by just looking at them. Shewould spend hours and hours browsing through an old Encyclopedia, looking at the pictures of human body, homogenesis phases and even insect behaviour. Her restless mind caused her agreat deal of problems in kindergarten since sheoften refused to go to bed during the afternoon sleep-time and, often, she would even take abook from the small kindergarten library and read it, hidden under the duvet, while other kids were sleeping. When Zuzana was five, her mother realised that the kindergarten was noplace for her daugther, and therefore, with the approval of experts, Zuzana was admitted to primary school ayear earlier than regular . That was where the real journey started, says Zuzana.

The competitive atmosphere of school brought Zuzanas ambitions and her desire to thrive to life. Even though shewas more than ayear younger than her classmates, she always perfomed very well and was one of the best pupils in her class. Although Zuzanastill preferred to read books, shefelt aresponsibility for the community and mediated with teachers and pupils about potential improvements to make; therefore she was electedclass representative.

Until the age of eleven her hobbies were pretty general: reading, playing the piano and dancing. Zuzanas interests changed when she was in sixth grade, as at that time, biology and chemistry classes were added to school curriculum. Zuzana was fascinated by the two new subjects and used to spend several hours each day to read popular science books and magazines. At the age of twelve sheperformed her first study about human body mass index (BMI) and obesity and took part in a local competition.

Due to her ambition and success in and outside school, she got the chance to study at GBAS Suany, aprestigious Slovak bilingual grammar school, where she started at the age of thirteen, and joined classes with classmates 3 years older than her.

During the biology classes, especially on the topics of neuroscience and genetics, Zuzana realised that although her desire for more knowledge was being fulfilled, her ambitions to do her own investigations and actuallycontribute to science were not satisfied. While looking for opportunities to collaborate with reasearch labs, she discovered that in many Western countries it is not uncommon for youngstudents to doscientific internships. She started contacting research institutions in Slovakia, but never was selected because of her young age. Consequently she started to applyoutside her home country and was eventually accepted as a summer intern at Masaryk University in Brno, Czech Republic at the Department of Histology and Embryology.

The laboratories that gave Zuzana this opportunity was lead by Mgr. Da Bohaiakov, Ph.D. and focused on neurogenesis research. The project she worked on was the immunofluorescent analysis of in vitro neural rosette formation from induced pluripotent stem cells (iPSCs). The aim of her research was to analyse the markers of neural rosette formation, which is a2D in vitro model of human neurogenesis. During the neurulation phase of embryogenesis there are many things than may go wrong, which can lead to neural tube defects (NTDs), such as spina bifida. NTDs are very dangerous and cause alot of pain and suffering in an individuals life. However, these days we are not only unable to treat these disorders, but we are not even able to observe the neurulation process non-invasively. That is why scientists are trying to developwith the in vitro solutions, which neural rosettes might potentially be.

Zuzanas first laboratory internship marked some new beginnings in her life such as the her first successfull research project, and afirst scientific work that won the 3rd place at the national Stredokolsk Odborn innos (High School Scientific Activity). At the age of 15 shewas the youngest participant in history.

The success of her first project was the incentive for Zuzanato participate in more scientific activities; therefore during the following term she launched abiology club at her school, took part in an international DNA essay contest where she finished among the top ten participants and carried out more work in a laboratory and completed one more internship.

In spite of all her success Zuzana still feels the responsibility for her community and she thinks that if shecould achieve all of this, why not any other student in the world? This is the reason why she decided to publish her story

Iam certainly no better than any other child, she says, yet Iwas lucky, Ihad an idea and enough passion not to give up, even though the circumstances were against me.

Zuzana hopes that her story can motivate her fellow pupils and she urges parents to foster the curiosity and ideas of their children. Additionally she wants to send the message that is importnat to look outside your own surrounding and use the possibilities Europe of today gives to everyone.

By Zuzana Hudacova

Featured image credit: Zuzana Hudov

Like Loading...

Related Posts

Go here to see the original:
Story of a 15-year old scientist: How it all began - EuroScientist

Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI – Xconomy

By Induced Pluripotent Stem Cells

XconomySan Diego

Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together.

San Francisco-based Atomwise has developed deep learning techniques for use in structure-based small molecule drug discovery. Since 2012 it has raised more than $50 million to bolster the development and application of its tech, which has been used by pharmaceutical and agrochemical companies, as well as by universities and hospitals across 40 countries. It says its computational tools can quickly analyze billions of compounds and thereby speed up the process of identifying compounds that bind to disease-causing proteins.

Stemonix, which has offices in Maple Grove, MN, and in San Diego, has developed models for testing potential drugs from human induced pluripotent stem cells, creating what it calls living microtissues to mimic human organs, including the brain and heart. The startup reported raising a $14.4 million Series B earlier this year to speed the commercialization of its platforms. Its MicroOrgans technology provides 3D disease models that the company hopes will give researchers a more accurate indication of whether compounds are likely to work in humans.

This is especially difficult to determine when it comes to finding drugs that work on rare neurological diseases, which are tricky to replicate in animal models because of the complexity of the human brain, according to Stemonix.

Atomwise has struck a number of deals with biotech and pharma companies interested in its tech, including Atropos Therapeutics, Hansoh Pharma, and Eli Lilly (NYSE: LLY). Financial terms of this latest deal werent disclosed.

The companies plan to use Atomwises AI and Stemonixs human MicroBrain 3D disease model to target Rett syndrome, a severe neurological disorder caused by mutations in the MECP2 gene. The gene encodes a protein thats needed for the development of the nervous system and normal brain function. Babies with the condition, most often infant girls, typically develop normally for the first 6 to 18 months of life before symptoms kick in. Then, they experience a progressive loss of motor skills and speech.

Some medications are used to ameliorate their symptoms, but no FDA-approved treatment exists. A number of companies are in human testing with experimental drugs for the condition.

Those in late-stage testing include Newron Pharmaceuticals, which is developing an experimental drug called sarizotan that aims to reduce patients episodes of apnea, or breathing disturbances, and San Diegos Acadia Pharmaceuticals, which last year licensed trofinetide, an investigational treatment targeting the disease, from Australias Neuren Pharmaceuticals.

The UKs GW Pharmaceuticals (NASDAQ: GWPH) is studying non-psychoactive parts of cannabis, including cannabidiol and cannabidivarin, as potential treatments.

Novartis (NYSE: NVS) subsidiary AveXis is also advancing a gene therapy for Rett, but in August said that its advancement to human testing would be delayed so it could redo and add to preclinical studies. The decision was made following revelations that some of the animal data the company submitted to the FDA in support of onasemnogene abeparvovec (Zolgensma), the gene therapy it developed for babies with spinal muscular atrophy, had been manipulated. Novartis acquired AveXis in 2018.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Read the original:
Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI - Xconomy

→←